共 48 条
- [21] Improved Outcome of Elderly Poor-Prognosis DLBCL Patients with 6xCHOP-14 and 8 Applications of Rituximab (R) Given Over An Extended Period: Results of the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)BLOOD, 2011, 118 (21) : 272 - 273Pfreundschuh, MichaelHeld, GerhardZeynalova, SamiraPoeschel, ViolaViardot, AndreasHaenel, MatthiasKeller, UlrichReiser, MarcelLoeffler, MarkusMurawski, Niels
- [22] Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab:: Results of the DENSE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL)ANNALS OF ONCOLOGY, 2008, 19 : 99 - 100Pfreundschuh, M.Zeynalova, S.Poeschel, V.Haenel, M.Schmitz, N.Ho, A. D.Reiser, M.Loeffler, M.Schubert, J.
- [23] Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Pfreundschuh, M.Zeynalova, S.Poeschel, V.Haenel, M.Schmitz, N.Ho, A. D.Reiser, M.Loeffler, M.Schubert, J.
- [24] Randomized Trial Comparing R-chop-14 Versus High Dose Sequential Chemotherapy in High Risk Patients with Diffuse Large B-cell Lymphomas. Final results from the GITIL-RHDS0305 studyBONE MARROW TRANSPLANTATION, 2016, 51 : S40 - S41Rambaldi, A.Tarella, C.Gianni, A. M.Ladetto, M.Barbui, A. M.Rossi, A.Gritti, G.Corradini, P.Di Nicola, M.Patti, C.Mule, A.Zanni, M.Zoli, V.Billio, A.Castellino, C.Di Raimondo, F.Ferreri, A.Benedetti, F.La Nasa, G.Gini, G.Trentin, L.Frezzato, M.Flenghi, L.Falorio, S.Masciulli, A.Delaini, F.Boschini, C.Cortelazzo, S.
- [25] Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+B-Cell Lymphomas: Effect of Rituximab on GraftVersus- Host Disease-Free/Relapse-Free Survival (GRFS)BLOOD, 2016, 128 (22)Dodero, AnnaPatriarca, FrancescaMilone, GiuseppeSarina, BarbaraMiceli, RosalbaIori, Anna PaolaBarretta, FrancescoTerruzzi, ElisabettaMussetti, AlbertoPini, MassimoBosi, AlbertoDominietto, AlidaCascavilla, NicolaOnida, FrancescoNarni, FrancoFarina, LuciaRambaldi, AlessandroCorradini, Paolo
- [26] Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High - Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)BLOOD, 2009, 114 (22) : 168 - 168Schmitz, NorbertNickelsen, MaikeZiepert, MaritaHaenel, MatthiasBorchmann, PeterViardot, AndreasNickenig, ChristinaBentz, MartinPeschel, ChristianTruemper, LorenzLoeffler, MarkusPfreundschuh, MichaelGlass, Bertram
- [27] A GITIL prospective randomized multicenter phase III study of high dose sequential chemotherapy with rituximab (R-HDS) and autologous transplantation (ASCT) of peripheral blood stem cells versus CHOP and rituximab delivered every 14 days (R-CHOP-14) in high-risk patients with diffuse large B-Cell lymphomas (DLBCL): Interim analysis on feasibility and toxicity (protocol R-HDS 0305).BLOOD, 2007, 110 (11) : 563A - 563ACortelazzo, SergioBillio, AttoRambaldi, AlessandroTarella, CorradoMajolino, IngnazioGianni, Alessandro M.Corradini, PaoloPatti, CatterinaMirto, SalvoBorrelli, GiovannaMarchioli, Roberto
- [28] Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL).BLOOD, 2009, 114 (22) : 1431 - 1431Pfreundschuh, MichaelMurawski, NielsZeynalova, SamiraPoeschel, ViolaReiser, MarcelHo, Anthony D.Nickenig, ChristinaWessendorf, SwenMetzner, BerndGrass, SandraSchubert, JoergLoeffler, MarkusSchmitz, Norbert
- [29] Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HD50305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL)BLOOD, 2012, 120 (21)Cortelazzo, SergioTarella, CorradoGianni, Alessandro MassimoBarbui, TizianoLadetto, MarcoBarbui, Anna MariaRossi, AndreaCorradini, PaoloDi Nicola, MassimoPatti, CaterinaMule, AntoninoZanni, ManuelaZoli, ValerioBillio, AttoGallamini, AndreaDi Raimondo, FrancescoFerreri, Andres J. M.Pizzolo, GiovanniLa Nasa, GiorgioLeoni, PietroSemenzato, GiampietroFrezzato, MaurizioFlenghi, LeonardoScarano, MarcoMasciulli, AriannaMarchioli, RobertoRambaldi, Alessandro
- [30] Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)BLOOD, 2020, 136Frontzek, FabianZiepert, MaritaNickelsen, MaikeAltmann, BettinaGlass, BertramHaenel, MathiasTruemper, LorenzHeld, GerhardBentz, MartinBorchmann, PeterDreyling, MartinViardot, AndreasKroschinsky, Frank P.Metzner, BerndStaiger, Annette M.Horn, HeikeOtt, GermanRosenwald, AndreasLoeffler, MarkusLenz, GeorgSchmitz, Norbert